InvestorsHub Logo
Followers 211
Posts 32178
Boards Moderated 1
Alias Born 06/30/2009

Re: HolesInMyPockitz post# 267066

Monday, 07/08/2019 10:39:04 AM

Monday, July 08, 2019 10:39:04 AM

Post# of 403103
"Interesting read on Bio-Pharma deals. Seems like some deals can take 12-15 months...."

Ironically your "read" was first posted here 18 months ago.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=137850767&txt2find=pullan

Here's how that post started:
"I am afraid that people are expecting Leo to deliver lightning speed negotiations."

...but it had a strange ending that seems inconsistent with your and its author's point:
"Patience. And comfort yourself with another quote from Dr. Pullan:
"the faster a deal progresses the more likely it is to come to a successful conclusion.""


Here's the whole sentence:
"Despite the inevitability of time elapsing, it’s important to remember that the faster a deal progresses the more likely it is to come to a successful conclusion."
And her preceding sentence:
"From the point when the other party has decided to go forward with term sheet negotiations, it can take another six to twelve months to get to a signature on a full agreement."

Her experience speaks for itself:
"Linda M. Pullan, Ph.D. offers biotech and pharmaceutical companies consulting in all
aspects of partnering through Pullan Consulting (www.pullanconsulting.com). Linda has a
Ph.D. in Biochemistry and a B.S. in Chemistry. Linda has more than 20 years of drug industry
experience, beginning in drug discovery at Monsanto/Searle/now Pfizer and
ICI/Zeneca/now AstraZeneca. After doing licensing at what is now AstraZeneca, Dr. Pullan
continued as head of oncology and hematology licensing for Amgen. She then joined
Kosan Biosciences as VP of Business Development and experienced all the tasks of outlicensing
and business development in a small company. For several years, she has been
providing companies help in identification, evaluation, valuation, negotiation and strategy for partnering in or out.
She has an extensive deal sheet ranging from company acquisitions to Phase III compounds and from preclinical
candidates to technologies, with both in- and out-licensing."

But can it core A apple?
Yes Ralph, of course it can core A apple.

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent IPIX News